AnaptysBio completes spin-off of First Tracks Biotherapeutics in corporate reorganization

AnaptysBio, Inc.

AnaptysBio, Inc.

ANAB

0.00
  • AnaptysBio completed spin-off of First Tracks Biotherapeutics, separating its former biopharma operations business.
  • Company will now operate as royalty management business focused on Jemperli royalties under collaboration with GSK.
  • Strategy also centers on imsidolimab royalties tied to Vanda collaboration.
  • AnaptysBio shifted to virtual model with limited headcount, minimal operating expenses, targeting more than 95% EBIT margin.
  • Reorganized company reported approximately $140 million-$145 million in net cash.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604200915PRIMZONEFULLFEED9692772) on April 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.